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Background: Chronic Obstructive Pulmonary Disease (COPD) is a disease state characterized by airflow limitation
that is not fully reversible and usually progressive. Current guidelines, among which the Dutch, have so far based
their management strategy mainly on lung function impairment as measured by FEV1, while it is well known that
FEV1 has a poor correlation with almost all features of COPD that matter to patients. Based on this discrepancy the
GOLD 2011 update included symptoms and impact in their treatment algorithm proposal. Health status measures
capture both symptoms and impact and could therefore be used as a standardized way to capture the information
a doctor could otherwise only collect by careful history taking and recording. We hypothesize that a treatment
algorithm that is based on a simple validated 10 item health status questionnaire, the Clinical COPD Questionnaire
(CCQ), improves health status (as measured by SGRQ) and classical COPD outcomes like exacerbation frequency,
patient satisfaction and health care utilization compared to usual care based on guidelines.
Methods/Design: This hypothesis will be tested in a randomized controlled trial (RCT) following 330 patients for
two years. During this period general practitioners will receive treatment advices every four months that are based
on the patient’s health status (in half of the patients, intervention group) or on lung function (the remaining half of
the patients, usual care group).
Discussion: During the design process, the selection of outcomes and the development of the treatment
algorithm were challenging. This is discussed in detail in the manuscript to facilitate researchers in designing future
studies in this changing field of implementation research.
Trial registration: Netherlands Trial Register, NTR2643Background
Chronic Obstructive Pulmonary Disease (COPD), a
common preventable and treatable disease, is characterized
by persistent airflow limitation that is usually progressive
and associated with an enhanced chronic inflammatory
response of the airways and the lungs to noxious particles
or gases [1]. COPD has a considerable impact on health
status [2]. Most guidelines, amongst which the 2003 Global
initiative for Chronic Obstructive lung Diseases (GOLD)
guidelines [3], and the Dutch GP guideline [4], have based
severity categorization on lung function impairment, more
specifically the FEV1. It is, however, well known that the* Correspondence: j.w.h.kocks@umcg.nl
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reproduction in any medium, provided the orFEV1 has a poor correlation with almost all patient
reported outcomes in COPD and therefore the impact the
disease has on the patient [5].
The GOLD strategy document update December 2011
[6] is the first update in which symptoms and exacerbations
are included in patient assessment and severity grading.
However a detailed management strategy is not included.
As far as the authors know, there currently is no study in
which the severity grading is tested via prospective
algorithms. This may be one of the reasons that the GOLD
update has not yet been incorporated in national guidelines.
Health status instruments have been developed specif-
ically to assess disease severity, measure disease impact
and to evaluate treatment. The use of validated health
status instruments in daily clinical practice offers a wide
range of opportunities. Information can be collected in a
standardized manner prior to consultation. This may
help decrease the known underestimation by clinicianstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients quality of life [7,8] and make it easier to review
the patients condition over longer periods of time [9].
Studies have also shown that patient satisfaction is
improved and patient opinions are more positive when
quality of life questionnaires form part of routine practice
[8,10]. High patient satisfaction is known to lead to superior
compliance [11,12], to more promptly seeking medical care
[13] and to retaining a higher amount of information
[14]. One of the important prerequisites for using a
questionnaire in routine clinical care, is its validation
on individual patient level. Most questionnaires have
solely been validated for the use in groups of patients.
Validation on the individual level requires a different
methodology. In the field of COPD this is currently
only performed for the CCQ [15,16].
The 2003 GOLD guidelines, on which Dutch national
guidelines are based, advocate a stepwise algorithm based
on FEV1 level, differentiation is only recommended on the
level of pharmacological treatment recommendations. All
non-pharmacological recommendations are identical for
all levels of severity, limiting individual differentiation.
We propose that health status instruments provide
the opportunity for individually tailored advices, focusing
on functional status, mental status and symptoms. A form
of tailoring that is, in a certain way, akin to the rising
interest in pheno typing patients to target interventions
more effectively [17].
Studies carried out in routine clinical practice show
promising results regarding the feasibility of the use of
health status instruments and their influence on the
consultation, however until now these studies have not
been able to show consistent benefits on outcomes for
patients with COPD [18-20]. These ambiguous results
might be due to differences in questionnaires used and
in the way studies were performed. Studies that test the
clinical effectiveness of health status instruments have
used a large variety of tools, settings, and outcome
parameters [18-26]. However none of these studies used
a clear algorithm on how to interpret the outcome of
health status measures nor did they feature clear advice
regarding patient management.
The 2013 GOLD update includes both the COPD
Assessment test (CAT) and the Clinical COPD
Questionnaire (CCQ) as health status measurements
[1]. One of the advantages of the CCQ over the CAT is its
domains. This enables identification of the patients’ prime
problem and thereby a focusing of the treatment on this
problem. Also, the CCQ was rated to be more useful in
primary care practice [27,28] and has been validated for
use in individual patients [15].
We hypothesize that a treatment algorithm that is
based on a simple validated measure of health status,
the Clinical COPD Questionnaire (CCQ), improveshealth status (as measured on a separate scale) and
secondary parameters like exacerbation frequency,
patient satisfaction and health care utilization, when
compared to usual care based on FEV1 level as per
current GOLD guidelines.
The research questions addressed are:
1. Does a treatment algorithm that is based on CCQ
measurements improve health status as measured by
SGRQ over two years of use compared to usual care
based on FEV1?
2. Does such a treatment algorithm improve other
parameters of COPD care such as exacerbation
frequency, mental health, health care utilization and
direct medical costs compared to usual care based
on FEV1?
This study combines the advantages of standardized
health status measurement in routine clinical practice
and of clear clinical treatment recommendations.
Methods/Design
Study design
The study will be a prospective randomized controlled
trial with a follow-up duration of two year with two arms:
 intervention group with CCQ guided treatment
proposals (CCQ group) and
 guideline group for whom treatment advice is based
on FEV1 level according to Dutch National and
GOLD guidelines (Usual Care, UC group).
The study flow-chart is represented in Figure 1. The
study has been approved by the Medical Ethical Committee
of the University Medical Center Groningen and is
registered on the Dutch trial register (ISRCTN-register)
with the identifier NTR2643.
Duration
Patients will be followed up for 2 years and during that
period there will be 7 visits, including a baseline and a
final visit (Figure 1).
Selection and recruitment
Local general practitioners will be contacted to participate
in the study. When a general practitioner agrees to partici-
pate, he/she is asked to review his/her patient database for
possible participants. The resulting eligible patients are sent
a patient information leaflet and an informed consent
form by their general practitioner. They will be asked
by letter to return the informed consent form to their
general practitioner if they wish to participate in the study
(opt-in method). The patients will then be invited for the
baseline visit. The inclusion criteria are a doctor’s diagnosis
Figure 1 MARCH study flow chart.
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at least 10 pack-years and a post bronchodilator
FEV1/ forced vital capacity (FVC) <0.70. Exclusion
criteria are a myocardial infarction less than 3 months
ago, inability to read and understand the Dutch language,
history of asthma or allergic rhinitis, regular use of
oxygen, unstable or life-threatening co-morbid condition
(as judged by the investigator) and dementia.
This study will take place in general practices in the
Northern part of the Netherlands. All measurements
including spirometry will be performed by a trained
research nurse and will take place in or near the GP
practices when possible.
Randomization and blinding strategy
After inclusion into the study the patients will be
randomized to the intervention or usual care group
using a computerized randomization on individual
patient level. The study will be performed in a
double-blind fashion, patients and doctors will be
blinded as well as the technicians that perform the
measurements. A separate researcher will collect the
data, and feed them in to a PC for a computerized
treatment advice based on pre-defined criteria as per
protocol. This advice will be sent to the doctor. Since the
doctor will only see the resulting treatment advices, and
not the measurement results they are based on, and since
the treatment advices are compliant with the same
national guide lines in both groups, albeit organized in a
different fashion, blinding is maintained.
Intervention
The actual intervention is the provision of treatment
advices to the general practitioner based on health status
in the CCQ group and based on FEV1 in the UC group.
Algorithm development
Algorithm objective
CCQ group: the primary objective during the develop-
mental phase was that the algorithm should result in astrategy that would treat the patient’s prime problem,
reflected by the most impaired CCQ domain and not treat
the remaining CCQ domains. At the next visit, it is
assessed whether the impairments in the specific domain
had improved sufficiently, the domain that is most
impaired at that moment will guide the next period of
treatment. The treatment intensity is guided by the CCQ
total score, i.e. the overall impairment in health status.
UC group: this algorithm resulted directly from the
treatment steps in the Dutch general practitioners
guidelines.
Algorithm content
CCQ group: all current standard treatments options in
the current Dutch general practitioners guidelines [4]
were reviewed (JWHK) (pharmacological, stop-smoking,
reactivation, counseling etc.) and rated on intensity of
the treatment and expected possible effects of the treat-
ment on each CCQ domain: symptoms, functional status
or exercise capacity and mental state (JWHK, TvdM,
HAMK). Subsequently the interventions were ordered
according to intensity of the treatment and resources
needed, e.g. for functional status this resulted in the
following ordering: physical activity advices, out-patient
reactivation, and rehabilitation.
UC group: all treatment steps in the Dutch general
practitioners guidelines were directly translated into the
algorithms.
Algorithm tuning
CCQ group: The concept treatment algorithm was
discussed during an 45 minute meeting with
pulmonologists and residents (n~15 present) working at
the University Medical Center Groningen and during
an one hour Groningen Research Institute for Asthma
and COPD (GRIAC) research meeting. This GRIAC
meetings are attended by both clinical and basic
scientists of the departments of allergology, lab
allergology and pulmonary diseases, epidemiology, general
practice, molecular pharmacology, pathology, paediatric
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respiratory insufficiency. The concept algorithm was slightly
altered as a result of these two meetings.
UC group: no further discussion nor fine tuning
took place.
Algorithm feasibility
CCQ and UC group: to assess feasibility of the final
algorithm, the algorithm was tested on databases of
previous studies in the Wilhelmina Hospital Assen
(n=38) and the Isala klinieken Zwolle (n=168).
Algorithm example
CCQ group: a high score on CCQ total score (>3, i.e.
severely impaired) in combination with the highest
score on the functional status domain leads to a pulmonary
rehabilitation program advice, while a total CCQ score
between 1 and 2 in combination with the highest
score on the functional status domain leads to the
provision of leaflets on healthy movement. A CCQ
total score < 1 represents a very low burden of disease or
good disease control, so no change in treatment advice is
given. The final algorithm is displayed in Figure 2.
UC group: the advise is taken directly from the treatment
steps in the Dutch general practitioners guidelines, a
GOLD III score leads to the advise to use both a
short acting and a long acting bronchodilator. In case
of more than 2 exacerbations per year also the use of
inhalation corticosteroids is advised.
Measurements
Baseline visit and last visit
At each visit, the disease should be stable; in case of an
exacerbation visits are postponed, there should be at
least 6 six weeks between the end of the exacerbation
and the visit. The following parameters are gathered at
baseline and last visit:
 Patient demographics: age, gender, marital status,
educational level, employment status.
 COPD specific information: smoking status, pack
years, duration of COPD.
 Previous participation in a formal smoking cessation
program, pulmonary rehabilitation or reactivation
program.
 Co-morbidities, using the Charlson comorbidity
index [29].
 Medication use and exacerbations in the last year.
Exacerbations are defined as an increase in or new
onset of more than one respiratory symptom
(cough, sputum, sputum purulence, wheezing,
dyspnea) with a duration of two or more days
requiring treatment with an antibiotic and/or
systemic steroid [30]. Spirometry, pre- and postbronchodilator FEV1 in
liters, FEV1 % predicted, FVC %predicted, and
inspiratory capacity. The bronchodilator will be
administered as salbutamol 4 times 100 microgram
per metered dose inhaler with chamber device.
 Body Mass Index
 Functional exercise capacity as measured by the 6
minute walking test [31]. The patients are asked to
walk up and down a level 30 meter walkway for 6
minutes. Breaks are allowed if necessary and recorded.
Total distance walked is recorded as well as heart rate,
blood pressure, Borg dyspnea score and oxygen
saturation immediately before and after the test.
 Patient reported outcomes:
 The SGRQ is a 50-question, 76-item, health
status scale for COPD patients. The SGRQ has
3 subscales: symptoms, activities and impact.
The score ranges from 0 (best) to 100 (worst).
The minimal clinically important difference is
4 points [32,33].
 The Clinical COPD Questionnaire is a 10-item
health status scale measuring three domains:
symptoms, functional status and mental state of
COPD patients. Scores range from 0 (best) to 6
(worst). The minimal clinically important
difference is 0.4 [34,35]. The CCQ has also been
validated on the individual patient level [15].
 The modified Medical Research Council (mMRC)
dyspnea scale [36]. This measures dyspnea on a
scale of 0 (not breathless except when performing
strenuous exercise) till 4 (too breathless to leave
the house or breathless when dressing).
 The Hospital Anxiety and Depression Scale, a
scale developed to identify anxiety disorders and
depression among patients in non-psychiatric
hospital clinics but also widely used outside the
hospital. It is divided into an Anxiety subscale
and a Depression subscale both containing seven
items. Each question is answered on a 0 to three
scale. A total score above 8 suggests the existence
of pathology. A change of 1.5 in each domain
score represents a clinically relevant change [37].
During each follow-up visit
The following is collected during each follow-up visit: spir-
ometry, pulmonary medication use, generic questionnaire
about treatment offered and received, unscheduled visits to
the GP or hospital because of pulmonary problems
and patient reported outcomes: CCQ, SGRQ, mMRC,
EuroQOL-5D and HADS.
Advices to health care providers
After each visit the GP receives a treatment advice.
Depending on the group to which the patient is
 Figure 2 CCQ based treatment algorithm.
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or on the Dutch National guidelines (UC group). In order
to check for compliance the GP is asked to report what
treatment (pharmacological and non-pharmacological) was
offered to the patient. If the GP deviates from this advice
he or she is asked to the provide the reason for deviating.Outcomes
Primary outcomes
The primary outcome is change in SGRQ over time.
Because the intervention is guided by the CCQ, a
different health status instrument, the SGRQ, is used
as primary outcome measure. Treatment of COPD
patients in primary care is focused on improvement
of health status and reduction of exacerbations. In
this perspective it is a logical choice to use a health
status questionnaire as an outcome measure.Secondary outcomes
One of the secondary outcomes is the exacerbation
frequency as indicated by medication use. This is one
of the classical COPD outcomes, and exacerbations
have a large impact on patients’ lives.
Other secondary outcome parameters are changes
in CCQ score, 6 minute walking distance test,
HADS, mMRC, lung function, and differences
between the two groups in hospital admissions and
mortality.Economical outcome variables
Health care utilization and other direct medical costs
are recorded. Data include medication use and all
visits to the general practice, hospital, and other
health care professionals involved in the management
of COPD.
Kocks et al. BMC Pulmonary Medicine 2013, 13:41 Page 6 of 9
http://www.biomedcentral.com/1471-2466/13/41Sample size calculation
Sample size calculations are based on difference in change
in health status between both groups. Because the interven-
tion is guided by the CCQ, an alternative health status
scale, the SGRQ, is used for the power-calculation. Based
on 80% power to detect the minimal clinically important
difference (4 points on the SGRQ) between the two groups,
a sample size of 150 persons per group is needed. The
standard deviation of the SGRQ total score in different
samples is approximately10-17 (12 used in calculation)
[38-42]. The alpha level was set at 0.05.
Taking dropouts into consideration, a sample size of
165 patients / group = 330 patients in total is aimed for.
Statistical analysis
The primary outcome measures is the change in SGRQ
over time. The SGRQ results in a total score and 3
subscale scores: symptoms, activities and impact. The
SGRQ change in scores over the treatment period of the
control group will be compared to that of the experimental
group. The scores will be tested for normality. In case of
normality the difference will be univariately tested with a
student T-test and multivariately with a linear regression
model. In case of deviation from normality the variable will
be transformed to normality via a Box-Cox transformation
and thereafter analyzed via student T-test and linear
regression models.The multivariate models will be
corrected for the following confounders: educational
level, age, gender, current smoking, and FEV1. The
number of exacerbations will be reported as weighted
exacerbations rates (total number of exacerbations divided
by the total person-time of follow up per group) [43-45].
Statistical significance of weighted rate ratios will calculated
using a Poisson regression model. The secondary research
outcomes will be tested in a similar fashion as the primary
research question. The primary analyses will be based on
the intention-to-treat principle. As secondary analyses, a
per protocol analysis will be performed to increase insight
in the data.
Discussion
The objective of the MARCH study is to study whether
a treatment algorithm that is based on health status as
measured by CCQ improves health status as measured
by SGRQ after two years of use compared to care based
on FEV1 levels as per regular (GOLD) guidelines.
This study is based on the assumption that treatment
based on problems that matter to patients (as reflected in a
health status measurement) will have more positive
effect on their life than treatment that is based on a
single measurement that has little relation with their
problems (FEV1).
The selection of an appropriate primary outcome meas-
ure for the current study was an important issue during thedesign process. The traditional primary outcome measure
in COPD research is lung function, usually represented by
the FEV1. The US Food and Drug Administration (FDA)
and the European Medicines Association (EMA) still
routinely require this in pharmaceutical trials. However,
FEV1 has been found to have a very poor correlation with
markers of COPD that seem to matter most to patients,
such as exercise tolerance, symptoms and also health status
[46,47]. Therefore, currently most researchers regard
changes in patient centered outcomes such as health status,
symptoms, exacerbations and functional status more
important than changes in lung function [47]. Patient
centered outcomes better reflect the complexity and the
impact of the disease, and several aspects of health status
predict clinically meaningful outcomes in COPD [48,49].
For instance, functional status as measured in health status
questionnaires has been shown to predict exacerbations
[50,51], hospital admissions [50-54] and mortality [55,56].
In most large scale COPD studies, health status is measured
and demonstrated to improve after successful interventions,
but it is seldom used as primary outcome. The situation is
different in pulmonary rehabilitation studies where health
status has been used as one of the primary endpoints [57].
Using health status as primary outcome measure in a
study where the treatment in one arm is organized
according to health status carries the risk of direct influence
on the outcome. In order to reduce this potential
methodological problem, a different health status
questionnaire (SGRQ) is used in our study instead of the
questionnaire that is used to guide the treatment (CCQ).
In the current study we decided to randomize on
the patient level and not on the GP cluster level. This
decision was made after careful evaluation of advantages
and disadvantages of randomization on the individual and
the cluster level. In this evaluation the following factors
played a pivotal role. A large disadvantage of cluster
randomization is the risk of selective inclusion, i.e. the
physician is more likely to discover to which treatment
group all his or her patients are allocated and this might,
unconsciously, play a role in selecting patients for participa-
tion in the study. A second large disadvantage is the need
for a much larger study population to maintain sufficient
power. An additional power calculation assuming 10 COPD
patients per practice, and a correlation of SGRQ within
primary care practices scores of 0.14 (based on previous
unpublished studies in our group), the total number of
patients needed to achieve a power of 0.8 is 462. This
constitutes an increase in patient number of 40%.
A disadvantage of randomizing at the individual level
is the risk of contamination, loss of allocation conceal-
ment. This risk is present on both the patient level and
on the physician level. On the patient level this is caused
by the fact that several patients from one GP practice
participate in this study and often patients in one
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control group might know patients that have been
randomized into the intervention group and via that
route receive information from the intervention group
which they then might decide to use for themselves.
However, we do not consider this to be a large risk in
our study because the experimental treatment does not
differ markedly from the usual care treatment, the same
treatment elements are used albeit differently organized.
In other words none of the patients will receive com-
pletely new and unexpected advices and therefore we
expect them to conform to the recommendations
given by their physicians.
The second level on which contamination might pose
a risk for the study is the physician level, physicians
might learn from the intervention and adjust their way
of working. We try to circumvent this risk by supplying
the physician with clear and individually tailored written
practical advices. Physician and patients are routinely
asked to report which treatment was given to each of
the participants in the study giving us an accurate
picture of whether or not contamination was present
and if so the size of the problem.
Health care providers are not used to interpreting health
status data. They need education and support to learn how
to interpret the scores of health status instruments if they
are to be successfully integrated into routine practice.
Greenhalgh’s review of health status studies concluded that
information should be fed back throughout the decision
making process to all clinicians involved in the patient’s
care and in a format they can make sense of and integrate
in clinical decision making [23]. Health status scores
should therefore be presented in a coherent clinically
relevant format, with clear guidelines for interpretation
and preferably with to-the-point recommendations. Based
on Greenhalgh’s suggestions we incorporated in our study
a clear treatment advice for the participating clinicians in
order to avoid difficulties around the interpretations of
health status scores.
Much effort was put in designing the treatment algo-
rithms, because this is a pivotal part of the study design.
During the design process choices without supporting
evidence had to be made, this is because treatment
based on health status is a novel concept and all previ-
ous studies were based on impairment of lung function
as treatment criterion. By discussing the algorithm in
different settings and with partners from various back-
grounds we tried to reduce possible bias.
Vital for successful completion of the study is compliance
of the care provider with the treatment advices. In the
current Dutch GP practice the care for patients with
chronic diseases is often transferred from the GP to the
practice nurse. This applies also to implementing treatment
advices. Practice nurses can achieve similar outcomes asdoctors in chronic disease management [58]. Additionally,
it has been demonstrated that practices in which the
organization is optimal, guidelines are better adhered to
[59]. Although this adds an extra layer in the process
from measurement (lung function or health status) to
effectuating the treatment, we are confident that in
well organized practices with practice nurses, our
advices will lead to similar results as with practices
that do not work with practice nurses.
Conclusions
This article describes the design of a double-blind random-
ized controlled trial in general practice that aims at demon-
strating that COPD care can be improved by implementing
a treatment algorithm based on a simple health care ques-
tionnaire. Considerations in choosing the primary end
point, the randomization procedure and the design of the
algorithm are described and result in decisions that both
support the scientific robustness and feasibility of this study.
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